Clinical Efficacy of Allo-HSCT on FLT3-ITD Positive AML Patients.
10.19746/j.cnki.issn.1009-2137.2020.04.011
- Author:
Hui ZHAO
1
;
Huan-Xu GUO
1
;
Fang XIAO
1
;
Dan FAN
1
;
Qiang LIU
2
Author Information
1. Department of Hematology，Tangdu Hospital of Air Force Medical University, Xi'an 710038, Shaanxi Province, China.
2. Department of Hematology，Tangdu Hospital of Air Force Medical University, Xi'an 710038, Shaanxi Province, China,E-mail：liuqiang@fmmu.edu.cn.
- Publication Type:Journal Article
- MeSH:
Disease-Free Survival;
Hematopoietic Stem Cell Transplantation;
Humans;
Leukemia, Myeloid, Acute;
Prognosis;
Remission Induction;
Retrospective Studies;
Treatment Outcome;
fms-Like Tyrosine Kinase 3
- From:
Journal of Experimental Hematology
2020;28(4):1152-1156
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To study the clinical efficacy of allo-HSCT on FLT3-ITD positive AML patients.
METHODS:The clinical data and curative efficacy of 56 FLT3-ITD AML patients treated with allo-HSCT in our hospital from January 2012 to December 2018 were analyzed and evaluated.
RESULTS:Neutrophil implantation was successful for all the patients; The median time of granulocyte hematopoietic reconstruction and megakaryocyte hematopoietic reconstruction was 13 (10-20) d and 15 (9-23) d respectively. The median follow-up time for patients 34.3 (5.6-101.4) months, 41 patients were alive and 15 patients dead at the end of follow-up. The 3 years-OS and -DFS rate was 71.2% and 65.6%, respectively. Univariate analysis showed that the OS rate of patients without aGVDH (81.2±9.4)% was significantly higher than that of patients with aGVDH (55.4±9.1) % (χ=5.309，P＜0.05). The OS rate of patients achieved CR after one chemotherapy course before allo-HSCT was (80.2±9.2)%, which was significantly higher than that of patients achieved CR after more chemotherapy courses (χ=4.275，P＜0.05). Cox multivariate survival analysis showed that CR after more chemotherapy courses and aGVDH after transplantation were risk factors for OS rate.
CONCLUSION:Allo-HSCT can improve the prognosis of FLT3-ITD AML patients. The patients achieved CR after one chemotherapy course before allo-HSCT and patients without aGVDH after allo-HSCT have a better prognosis.
